Merck’s New Cancer Drug Wins Speedy Approval in China
Pharmaceutical giant Merck Sharp & Dohme (MSD) has won approval to launch a cutting-edge cancer drug in China, a month after rival Bristol-Myers Squibb (BMS) obtained the go-ahead for its own such drug.
The MSD medicine, Keytruda, received the green light from the China Food and Drug Administration (CFDA) on Wednesday. The drug can cure certain levels of melanoma, a type of skin cancer.
- 1In Depth: Tesla Charges Into China
- 2China Biz Roundup Podcast: Factory Inflation Stalls, iPhone Discounts, and Private Kindergarten Closures
- 3Update: China’s New Credit Growth Hits Record High
- 4 Operators of ‘Underground Banks’ Which Move Cash Out of China to Face Jail
- 5In-Depth: Investment Group CMIG Starts Asset Sales Amid Liquidity Crunch
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas